Eli Lilly and Company Acquires Phase III Intranasal Glucagon from Locemia Solutions
Intranasal Glucagon Could be the First Needle-Free Rescue Treatment for Severe Hypoglycemia
INDIANAPOLIS, October 9, 2015 – Eli Lilly and Company (NYSE:LLY) and Locemia Solutions today announced Lilly has acquired worldwide rights to Locemia’s intranasal glucagon, a potential treatment for severe hypoglycemia in people with diabetes treated with insulin. Intranasal glucagon, which is currently in Phase III clinical trial testing, could be the first needle-free rescue treatment for severe hypoglycemia. Read the Lilly press release here.